Cargando…

Is immune checkpoint modulation a potential therapeutic option in triple negative breast cancer?

No abstract. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-014-0457-z) contains supplementary material, which is available to authorized users.

Detalles Bibliográficos
Autor principal:	Klinke, David J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303193/ https://www.ncbi.nlm.nih.gov/pubmed/25927347 http://dx.doi.org/10.1186/s13058-014-0457-z

Ejemplares similares

Immune checkpoints: A therapeutic target in triple negative breast cancer
por: Chawla, Akhil, et al.
Publicado: (2014)

Triple-Negative Breast Cancer: Adjuvant Therapeutic Options
por: Gucalp, Ayca, et al.
Publicado: (2011)

Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer
por: Camorani, Simona, et al.
Publicado: (2020)

ZDHHC9: a promising therapeutic target for triple-negative breast cancer through immune modulation and immune checkpoint blockade resistance
por: Xu, Chao, et al.
Publicado: (2023)

Management Options in Triple-Negative Breast Cancer
por: Minami, Christina A., et al.
Publicado: (2011)

Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
por: Poddar, Arpita, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker
por: Qureshi, Sadaf, et al.
Publicado: (2022)

Treatment options for patients with triple-negative breast cancer
por: Santana-Davila, Rafael, et al.
Publicado: (2010)

The Triple-Negative Breast Cancer Database: an omics platform for reference, integration and analysis of triple-negative breast cancer data
por: Raju, Rajesh, et al.
Publicado: (2014)

RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer
por: Tentler, John J., et al.
Publicado: (2020)

Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer
por: Tan, Qiaorui, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
por: Thomas, Remy, et al.
Publicado: (2021)

Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives
por: Yi, Huimei, et al.
Publicado: (2021)

Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
por: Ghallab, Ahmed
Publicado: (2020)

Metastatic and triple-negative breast cancer: challenges and treatment options
por: Al-Mahmood, Sumayah, et al.
Publicado: (2018)

Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
por: Heeke, Arielle L., et al.
Publicado: (2021)

Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
por: Abdou, Yara, et al.
Publicado: (2022)

Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer
por: Li, Chia-Jung, et al.
Publicado: (2021)

On the Therapeutic Potential of ERK4 in Triple-Negative Breast Cancer
por: Boudghene-Stambouli, Fadia, et al.
Publicado: (2022)

Ferroptosis and triple-negative breast cancer: Potential therapeutic targets
por: Xu, Na, et al.
Publicado: (2022)

Are triple-negative tumours and basal-like breast cancer synonymous?
por: Rakha, Emad A, et al.
Publicado: (2007)

ESMO20 YO for YO: highlights on immune checkpoint blockade for triple-negative breast cancer
por: Punie, K., et al.
Publicado: (2020)

Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 update()
por: Brown, Lauren C., et al.
Publicado: (2021)

Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance
por: Kim, Hyungjoo, et al.
Publicado: (2022)

Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer
por: Boissière-Michot, Florence, et al.
Publicado: (2022)

The Potential Role of Nanotechnology in Therapeutic Approaches for Triple Negative Breast Cancer
por: Johnson, Rebecca, et al.
Publicado: (2013)

Therapeutic potential of ERK5 targeting in triple negative breast cancer
por: Ortiz-Ruiz, María Jesús, et al.
Publicado: (2014)

Triple negative breast cancer: approved treatment options and their mechanisms of action
por: Mandapati, Aditya, et al.
Publicado: (2022)

Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
por: Obidiro, Onyinyechi, et al.
Publicado: (2023)

Opioids and immune checkpoint inhibitors differentially regulate a common immune network in triple-negative breast cancer
por: Scarpa, Joseph R., et al.
Publicado: (2023)

Therapeutic Potential of Thymoquinone in Triple-Negative Breast Cancer Prevention and Progression through the Modulation of the Tumor Microenvironment
por: Adinew, Getinet M., et al.
Publicado: (2021)

Therapeutic potential of Fingolimod in triple negative breast cancer preclinical models
por: Rupp, Tristan, et al.
Publicado: (2020)

Proteins Found in the Triple-Negative Breast Cancer Secretome and Their Therapeutic Potential
por: McHenry, Peter R., et al.
Publicado: (2023)

Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Munkácsy, Gyöngyi, et al.
Publicado: (2023)

Exploring immune interactions in triple negative breast cancer: IL-1β inhibition and its therapeutic potential
por: Wilson, Brooke E., et al.
Publicado: (2023)

Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer
por: Simmons, Christine E., et al.
Publicado: (2020)

Individual xenograft as a personalized therapeutic resort for women with metastatic triple-negative breast carcinoma
por: Bousquet, Guilhem, et al.
Publicado: (2014)

Are triple-negative tumours and basal-like breast cancer synonymous? Authors' response
por: Kreike, Bas, et al.
Publicado: (2007)

Leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer
por: Sardela de Miranda, Flávia, et al.
Publicado: (2023)

Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications
por: Jézéquel, Pascal, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hdt5luntqcu9ugdgg619fd3t01